Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MANÜ Telehealth vs Maves

MANÜ Telehealth
Graded #83

Higher grade

vs+0.4000000000000057
Maves
Graded #89

Lower grade

The verdict

MANÜ Telehealth takes it — 72.2/100 to 71.8/100, but only just.

MANÜ Telehealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MANÜ Telehealth is a US online platform offering compounded GLP-1 weight loss medication including injectable tirzepatide and semaglutide, with add-ons like MIC Ultraburn and NAD+ injections. Maves is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMANÜ Telehealth +1
85
84
Dose & formulationMaves +1
64
65
Clinical oversightMANÜ Telehealth +3
79
76
Labs & monitoringMANÜ Telehealth +11
63
52
FulfillmentMaves +16
71
87
Contract termsEven
55
55
MANÜ Telehealth · left barMaves · right bar

The numbers

MetricMANÜ TelehealthMaves
WeighScore72.2/10071.8/100
GradeCC
Scorecard rank#83#89
Semaglutide$120/mo (compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$150/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
MANÜ Telehealth

Graded #83 · C

Strengths

  • Compounded GLP-1s advertised from about $4-$5/day
  • 100% online with free discreet shipping and no insurance needed
  • Compounds exclusively from US 503A pharmacies
  • Add-on options like MIC Ultraburn and NAD+

Where it loses points

  • Per-dose pricing is gated behind login/signup, not public
  • State availability changes and is only confirmed at signup
  • Compounded medications are not FDA-evaluated
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard